Diet Induced Ketosis for Patients With Posttraumatic Stress Disorder (PTSD), a Feasibility Study

Sponsor
Jens Rikardt Andersen (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05415982
Collaborator
Oslo University Hospital (Other)
10
1
1
5.9
1.7

Study Details

Study Description

Brief Summary

Many patients suffering from posttraumatic stress disorder (PTSD) are resistant to established treatment consisting of psychotherapy. Patients often go years with this debilitating disorder without experiencing sufficient improvement. Approximately 1/3 of patients will drop out of treatment because of psychological burden and overactivation. A novel ketogenic diet treatment could amend established treatment, and potentially upregulate the threshold for exciting neurons in dysfunctional brain regions, mediated through various mechanisms. This may reduce PTSD symptoms, and thus enabling patients to respond to psychological treatment without getting overactivated and unable to process trauma. The purpose of this study is to investigate whether it is possible to carry out a ketogenic diet therapy for patients with PTSD for four weeks.

Condition or Disease Intervention/Treatment Phase
  • Other: Ketogenic Diet
N/A

Detailed Description

The study aims to include 10 PTSD patients. If a participant drops out of the study, or if the study is otherwise terminated for a participant, another patient will be recruited until 10 have completed the study. The primary objectives of this feasibility study are to investigate if it is possbile to carry out a ketogenic diet therapy for patients with PTSD for 4 weeks, and systematically gain insight in all challenges relating to these objectives. The participants will follow a ketogenic diet for 4 weeks, and they are asked to self report daily on results from finger pricking blood measurements (glucose and betahydroxybutyrate (BHB)) to establish they are in a ketogenic state and are compliant to diet. Participants will also report food intake and side effects daily to be evaluated by the principal investigator. Participants are further asked to specify and elaborate on which adverse effects or other reasons as to why it is challenging to follow the study diet and/or procedures. The study lacks in power to statistically evaluate if ketosis has any effect on PTSD symptoms, however this secondary objective will be preliminary evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Diet Induced Ketosis for Patients With Posttraumatic Stress Disorder (PTSD), a Feasibility Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Feb 28, 2023
Anticipated Study Completion Date :
Feb 28, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ketogenic Diet

Ketogenic Diet every day for 4 weeks

Other: Ketogenic Diet
The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,

Outcome Measures

Primary Outcome Measures

  1. Recruitment [25 weeks]

    How many patients can be included in the intervention group (percent out of all eligible patients during the inclusion period)

  2. Completing the intervention [4 weeks]

    How many patients complete the intervention of four weeks (percent out of all included patients) Completion is defined as adherence to the intervention daily for four weeks.

  3. Maintaining ketosis [4 weeks]

    Could ketosis (mean b-BHB ≥ 0,5 mmol/L out of three daily measurements) be maintained for the duration of intervention (percent out of intervention days since ketosis first was obtained)

  4. Adverse reactions related to the ketogenic treatment [4 weeks]

    The occurrence of adverse reactions (percent of days with adverse reactions during intervention)

Secondary Outcome Measures

  1. Assessment of severity of PTSD symptoms [4 weeks]

    Change in PTSD Checklist for DSM-5 scale (PCL-5). 20 part item, 0-4 likert scale. Minimum value 0, maximum value 80 (Lower score is better)

  2. Measure of Health-Related Quality of Life [4 weeks]

    Change in RAND 36-Item Health Survey 1.0 (RAND-36) - Scale is converted to numerical values for physical and mental health (each item is scored on a 0 to 100 range, so that the lowest and highest score are 0 and 100, respectively). Items in the same scale are averaged together to create 8 scale scores. A higher score defines a more faborable health state.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients 18-65 years

  • Diagnosed with posttraumatic stress disorder (PTSD)

  • Understand and speak Scandinavian language

Exclusion Criteria:
  • Body Mass Index < 18

  • Metabolic disorders contraindicating a ketogenic diet

  • Dysregulated Diabetes Mellitus

  • Medicated for elevated triglycerides

  • Pancreas, kidney or liver disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Søndre Oslo Distriktspsykiatriske Senter (DPS) Oslo Norway 1281

Sponsors and Collaborators

  • Jens Rikardt Andersen
  • Oslo University Hospital

Investigators

  • Principal Investigator: Tobias Furuholmen-Jenssen, Student, University of Copenhagen
  • Study Director: Jens R Andersen, MD, MPA, University of Copenhagen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jens Rikardt Andersen, Associate Professor, University of Copenhagen
ClinicalTrials.gov Identifier:
NCT05415982
Other Study ID Numbers:
  • Ketosis PTSD
First Posted:
Jun 13, 2022
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022